top of page
TARGIT-IORT outcomes from the TARGIT-A trial.png
TARGIT-IORT results of TARGIT-A trial.png

Note: As per the original trial protocol, as part of the risk-adapted approach, about 20% of patients allocated TARGIT-IORT were expected to receive whole breast radiotherapy due to factors found in post-operative microscopic examination of the tumour specimen.

This approach allows individualised and personalised treatment for each patient.

A tool to help decide when to use of additional radiotherapy is available at here or 

The short-term and long-term results of those received additional whole breast radiotherapy did not differ from those who did not or from those who were allocated whole breast radiotherapy.


At 5 years' complete follow up, local recurrence (LR) and death rates (Deaths) were: 

Allocated TARGIT-IORT during lumpectomy       LR 2.11%,   Deaths 3.7%, 

Allocated TARGIT-IORT received no EBRT           LR 2.35%,   Deaths 3.1%

Allocated Whole breast radiotherapy                   LR 0.95%,   Deaths 4.8%


The local control rates are shown in the figure below:

Figure 2.png


1.  Vaidya, J.S., et al., Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ, 2020. 370: p. m2836. 

2. Vaidya, J.S., et al., New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer. Br J Cancer, 2021. 125(3): p. 380-389.

3.  Vaidya, J.S., et al., Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment. British Journal of Cancer, 2021.


5. Vaidya, J.S., et al., The TARGIT-A Randomized Trial: TARGIT-IORT Versus Whole Breast Radiation Therapy: Long-Term Local Control and Survival. Int J Radiat Oncol Biol Phys, 2023. 115(1): p. 77 82. 


4. Vaidya, J.S., et al., Global adoption of single-shot targeted intraoperative radiotherapy (TARGIT-IORT) to improve breast cancer treatment – better for patients, better for health care systems. Frontiers in Oncology, 2022. 12: p. 786515.


bottom of page